126 related articles for article (PubMed ID: 16061869)
21. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Zhu H; Zhang L; Dong F; Guo W; Wu S; Teraishi F; Davis JJ; Chiao PJ; Fang B
Oncogene; 2005 Jul; 24(31):4993-9. PubMed ID: 15824729
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.
Ko BS; Chang TC; Chen CH; Liu CC; Kuo CC; Hsu C; Shen YC; Shen TL; Golubovskaya VM; Chang CC; Shyue SK; Liou JY
Life Sci; 2010 Jan; 86(5-6):199-206. PubMed ID: 20006625
[TBL] [Abstract][Full Text] [Related]
23. p300 and p53 levels determine activation of HIF-1 downstream targets in invasive breast cancer.
Vleugel MM; Shvarts D; van der Wall E; van Diest PJ
Hum Pathol; 2006 Aug; 37(8):1085-92. PubMed ID: 16867872
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
Van Waes C; Chang AA; Lebowitz PF; Druzgal CH; Chen Z; Elsayed YA; Sunwoo JB; Rudy SF; Morris JC; Mitchell JB; Camphausen K; Gius D; Adams J; Sausville EA; Conley BA
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1400-12. PubMed ID: 16005577
[TBL] [Abstract][Full Text] [Related]
25. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain.
Kaluz S; Kaluzová M; Stanbridge EJ
Mol Cell Biol; 2006 Aug; 26(15):5895-907. PubMed ID: 16847340
[TBL] [Abstract][Full Text] [Related]
26. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Amschler K; Schön MP; Pletz N; Wallbrecht K; Erpenbeck L; Schön M
J Invest Dermatol; 2010 Apr; 130(4):1073-86. PubMed ID: 19940859
[TBL] [Abstract][Full Text] [Related]
27. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
28. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.
Hamilton AL; Eder JP; Pavlick AC; Clark JW; Liebes L; Garcia-Carbonero R; Chachoua A; Ryan DP; Soma V; Farrell K; Kinchla N; Boyden J; Yee H; Zeleniuch-Jacquotte A; Wright J; Elliott P; Adams J; Muggia FM
J Clin Oncol; 2005 Sep; 23(25):6107-16. PubMed ID: 16135477
[TBL] [Abstract][Full Text] [Related]
29. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.
Hui EP; Chan AT; Pezzella F; Turley H; To KF; Poon TC; Zee B; Mo F; Teo PM; Huang DP; Gatter KC; Johnson PJ; Harris AL
Clin Cancer Res; 2002 Aug; 8(8):2595-604. PubMed ID: 12171890
[TBL] [Abstract][Full Text] [Related]
30. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
31. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
32. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.
Generali D; Fox SB; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield SM; Bruzzi P; Bersiga A; Allevi G; Milani M; Aguggini S; Dogliotti L; Bottini A; Harris AL
Endocr Relat Cancer; 2006 Sep; 13(3):921-30. PubMed ID: 16954440
[TBL] [Abstract][Full Text] [Related]
33. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
Trastour C; Benizri E; Ettore F; Ramaioli A; Chamorey E; Pouysségur J; Berra E
Int J Cancer; 2007 Apr; 120(7):1451-8. PubMed ID: 17245699
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.
Gomez-Abuin G; Winquist E; Stadler WM; Pond G; Degendorfer P; Wright J; Moore MJ
Invest New Drugs; 2007 Apr; 25(2):181-5. PubMed ID: 16983508
[TBL] [Abstract][Full Text] [Related]
35. Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX.
Korkolopoulou P; Perdiki M; Thymara I; Boviatsis E; Agrogiannis G; Kotsiakis X; Angelidakis D; Rologis D; Diamantopoulou K; Thomas-Tsagli E; Kaklamanis L; Gatter K; Patsouris E
Hum Pathol; 2007 Apr; 38(4):629-38. PubMed ID: 17367605
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells.
Min H; Xu M; Chen ZR; Zhou JD; Huang M; Zheng K; Zou XP
Cancer Chemother Pharmacol; 2014 Jul; 74(1):167-76. PubMed ID: 24842158
[TBL] [Abstract][Full Text] [Related]
37. A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.
Shah MA; Power DG; Kindler HL; Holen KD; Kemeny MM; Ilson DH; Tang L; Capanu M; Wright JJ; Kelsen DP
Invest New Drugs; 2011 Dec; 29(6):1475-81. PubMed ID: 20574790
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib.
Veschini L; Belloni D; Foglieni C; Cangi MG; Ferrarini M; Caligaris-Cappio F; Ferrero E
Blood; 2007 Mar; 109(6):2565-70. PubMed ID: 17110461
[TBL] [Abstract][Full Text] [Related]
39. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
[TBL] [Abstract][Full Text] [Related]
40. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
Fernández Y; Verhaegen M; Miller TP; Rush JL; Steiner P; Opipari AW; Lowe SW; Soengas MS
Cancer Res; 2005 Jul; 65(14):6294-304. PubMed ID: 16024631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
